Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

Lutetium Lu 177 dotatate was approved by the FDA for children aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Sarah Montini, BSN, RN, OCN, provides an in-depth look at abemaciclib for the treatment of patients with breast cancer in a downloadable reference sheet.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Superior 3-year survival outcomes were observed with durvalumab plus chemotherapy compared with chemotherapy alone in patients with advanced biliary tract cancer.

Breast-conserving therapy following preoperative systemic therapy resulted in superior overall survival compared with mastectomy in patients with HER2-positive breast cancer.